Please login to the form below

Not currently logged in
Email:
Password:

Ryzodeg

This page shows the latest Ryzodeg news and features for those working in and with pharma, biotech and healthcare.

Novo seeks to strengthen Tresiba label in US

Novo seeks to strengthen Tresiba label in US

Interim results from the 7, 500-patient DEVOTE study were instrumental in allowing Novo to get FDA approval for Tresiba and combination drug Ryzodeg in 2015, after being knocked back by

Latest news

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Nevertheless, the strong sales performance for Tresiba and other new insulin products - such as combination products Ryzodeg (insulin degludec/insulin aspart) and Xultophy (insulin degludec/liraglutide) - helped Novo Nordisk post a

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Last October however the Danish drugmaker finally won US approval for Tresiba and combination product Ryzodeg (insulin degludec and insulin aspart), prompting analysts at Sydbank to increase their peak sales predictions

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Novo Nordisk finally bags insulin degludec approval in US. Aims to get Tresiba and Ryzodeg back on course . ... Earlier this year however Novo Nordisk decided to refile Tresiba and Ryzodeg on the strength of interim data from the outcomes trial, called

  • Novo brings Xultophy to third European market Novo brings Xultophy to third European market

    US regulators dealt the company a major blow in February 2013 when marketing applications for Tresiba and Ryzodeg, which combines Tresiba with Novo's Novolog (insulin aspart), were rejected.

  • Novo Nordisk opens insulin facility in Russia Novo Nordisk opens insulin facility in Russia

    Last month, the firm revealed plans to resubmit its FDA marketing applications for diabetes therapies Tresiba and Ryzodeg after being rejected two years ago, with the regulatory body beginning its revaluation

More from news
Approximately 8 fully matching, plus 18 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics